FDA Clears Warner Chilcott’s Scalp Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Psoriasis salve lifts first-quarter revenue, ahead of $40 million milestone payout to Denmark firm Leo Pharma.
You may also be interested in...
Warner Chilcott Licenses Psoriasis Drug
Warner Chilcott has agreed to license Dovobet from LEO Pharma S/A upon FDA approval
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.